CSPC Innovation Pharmaceutical Co Ltd Class A300765
▲ PositiveCapitalrelevance
Company swung to profit with strong revenue growth and improved margins.

CSPC Innovation released its 2026 interim report, with net profit attributable to the parent company of 1.261 billion yuan, an increase of 1.264 billion yuan compared with the same period last year, turning losses into profits. The company's total operating revenue was 3.24 billion yuan, up 208.72 percent year on year, and net cash inflow from operating activities was 2.776 billion yuan. The latest gross margin was 76.74 percent, ROE was 32.04 percent, and diluted earnings per share was 0.91 yuan.
CSPC Innovation Pharmaceutical Co Ltd Class ACompany swung to profit with strong revenue growth and improved margins.